These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34331551)

  • 21. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting.
    Rajah SM; Nair U; Rees M; Saunders N; Walker D; Williams G; Critchley A; Beton D; Campbell C; Lawson RA
    J Thorac Cardiovasc Surg; 1994 Apr; 107(4):1146-53. PubMed ID: 8159037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen.
    Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I
    J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between high on aspirin platelet reactivity and oxidative stress in coronary artery by-pass grafted patients.
    Kuliczkowski W; Golanski R; Bijak M; Boryczka K; Kaczmarski J; Watala C; Golanski J
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):151-5. PubMed ID: 26523914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease.
    Wiseman LR; Fitton A; Buckley MM
    Drugs; 1992 Sep; 44(3):445-64. PubMed ID: 1382938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin.
    Bliden KP; Singla A; Gesheff MG; Toth PP; Tabrizchi A; Ens G; Guyer K; Singh M; Franzese CJ; Stapleton D; Tantry US; Gurbel PA
    Thromb Haemost; 2014 Aug; 112(2):323-31. PubMed ID: 24763965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
    Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
    Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood.
    Patrignani P; Volpi D; Ferrario R; Romanzini L; Di Somma M; Patrono C
    Eur J Pharmacol; 1990 Nov; 191(1):83-8. PubMed ID: 1965501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
    Rocca B; Tosetto A; Petrucci G; Rossi E; Betti S; Soldati D; Iurlo A; Cattaneo D; Bucelli C; Dragani A; Di Ianni M; Ranalli P; Palandri F; Vianelli N; Beggiato E; Lanzarone G; Ruggeri M; Carli G; Elli EM; Renso R; Randi ML; Bertozzi I; Loscocco GG; Ricco A; Specchia G; Vannucchi AM; Rodeghiero F; De Stefano V; Patrono C;
    Am J Hematol; 2024 Aug; 99(8):1462-1474. PubMed ID: 38877813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease.
    Chello M; Mastroroberto P; Celi V; Romano F; Marchese AR; Colonna A
    J Cardiovasc Pharmacol; 1996 Mar; 27(3):417-23. PubMed ID: 8907804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.
    Dmoszyńska A; Janicki K; Janicka L; Przesmycki K; Sokołowska B; Walter-Croneck A
    Pol J Pharmacol; 1996; 48(3):327-9. PubMed ID: 9112671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of indobufen on platelet thromboxane B2 production in patients with myocardial infarction.
    Rebuzzi AG; Natale A; Bianchi C; Mariello F; Coppola E; Ciabattoni G
    Eur J Clin Pharmacol; 1990; 39(1):99-100. PubMed ID: 2276396
    [No Abstract]   [Full Text] [Related]  

  • 36. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen.
    Mamiya S; Hagiwara M; Ishikawa T; Hidaka H
    Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis.
    Larsen ML; Pedersen OH; Hvas AM; Niekerk PBVK; Bønløkke S; Kristensen SD; Grove EL
    Platelets; 2019; 30(3):322-328. PubMed ID: 29442537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory activity of indobufen (*) on platelet aggregation in vivo.
    Bergamaschi M; Pierucci L; Branzoli U
    Pharmacol Res Commun; 1984 Oct; 16(10):979-85. PubMed ID: 6438651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
    DeFilippis AP; Oloyede OS; Andrikopoulou E; Saenger AK; Palachuvattil JM; Fasoro YA; Guallar E; Blumenthal RS; Kickler TS; Jaffe AS; Gerstenblith G; Schulman SP; Rade JJ
    Circ J; 2013; 77(11):2786-92. PubMed ID: 23985963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding time and antiplatelet agents in normal volunteers.
    Pogliani EM; Fowst C; Bregani R; Corneo G
    Int J Clin Lab Res; 1992; 22(1):58-61. PubMed ID: 1633323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.